The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.
about
Imaging the DNA damage response with PET and SPECTSynthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography.Base excision repair defects invoke hypersensitivity to PARP inhibition.A localized PCR inhibitor in a porcelain crab suggests a protective role.Targeting poly (ADP-ribose) polymerase partially contributes to bufalin-induced cell death in multiple myeloma cells.Elemental bioimaging of Cisplatin in Caenorhabditis elegans by LA-ICP-MSToward individualized breast cancer therapy: translating biological concepts to the bedside.Identification of new candidate therapeutic target genes in triple-negative breast cancerNon-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivoSmall PARP inhibitor PJ-34 induces cell cycle arrest and apoptosis of adult T-cell leukemia cells.Erythropoietin-driven signalling and cell migration mediated by polyADP-ribosylation.Addicted to PAR? A closer look at PARP inhibitor sensitivity.Therapeutic applications of PARP inhibitors: anticancer therapy and beyondDoxorubicin induced heart failure: Phenotype and molecular mechanisms.Crosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes.Natural inhibitors of poly(ADP-ribose) polymerase-1.Role of poly(ADP-ribose) polymerases in the regulation of inflammatory processes.The changing landscape of therapeutic strategies for recurrent ovarian cancer.PARP inhibitors in cancer therapy: an update.Poly(ADP-ribose) polymerase 1 (PARP1) in atherosclerosis: from molecular mechanisms to therapeutic implications.Current and emerging strategies to increase the efficacy of ionizing radiation in the treatment of cancer.PARP inhibitors for anticancer therapy.Advanced stage pancreatic cancer: novel therapeutic options.Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue.Molecular mechanisms of Mn induced neurotoxicity: RONS generation, genotoxicity, and DNA-damage response.PARP inhibitors protect against sex- and AAG-dependent alkylation-induced neural degeneration.Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome.PARPi potentiates with current conventional therapy in MLL leukemia.Evaluation of aromatic radiobromination by nucleophilic substitution using diaryliodonium salt precursors.FDA Approval of PARP Inhibitors and the Impact on Genetic Counseling and Genetic Testing Practices.Potential role of poly(ADP-ribose) polymerase (PARP) activation in methotrexate-induced nephrotoxicity and tubular apoptosis.
P2860
Q33581909-96AF6C9F-5659-4A89-8FC6-F2B662274EE4Q33607384-1BAB314D-4290-422F-BAE2-9D8A024BDAC3Q34053881-67303228-5AED-498C-AF35-37970188F689Q34658820-D7F88378-31CD-4ACB-B8D1-2C1F6AFAA064Q34770525-707A7312-A0AA-4D4C-964A-6EA5189F7700Q35638073-B077A4EC-E50D-4E47-BE4E-4D5799B1D413Q35913199-4402D1A0-5BB6-47C1-A9B2-6F41B12F478AQ36153325-1D6D2A5F-A9A6-44C0-BD49-095FC18C39FEQ36160278-747B3198-A7AB-4C4A-A06D-75F5F60FF9E8Q36203280-0C50FB33-1C29-4977-A246-0E16F16797A3Q36387871-42889435-F953-46AB-B6DE-D5F352541C94Q36426473-67B4A2FE-6F2F-467C-93DF-F5482456AA9BQ36853236-F0574A4E-E6EB-453B-A9F5-FB32160569DEQ36912561-3FF196A4-F376-4270-BCB9-CE7F5E602A42Q36913813-E2115EB9-A11E-4BDF-95DE-188C0187771FQ38000092-4290BBA8-AD3F-4C16-AF99-FB6122DCD4CAQ38047690-82B56D80-595F-4AFD-92BA-188282A7E346Q38048887-714F7FBE-1A54-4E45-9F99-DB9C3FBAB35DQ38078993-E447DA28-C3FB-4675-A078-DEEA8D70B71EQ38134049-22ED6F91-4AA1-4884-8BDC-88B9494C6417Q38174090-EED83D19-F513-4B4A-ABFB-D3A9B94FFC10Q38180762-97775D4B-6A89-415A-B465-EE16745995CEQ38221089-2BA43CAB-E1B7-45C0-8691-899FBB732DDEQ39069405-43287361-76A1-42CC-A3B0-AE9F85F23951Q39180806-150943C0-DE4F-42B9-9BC0-992B03575410Q42366639-EC74CB88-AC17-4AB7-A2F8-F7F563FEAA3CQ42378380-ECD45B25-C905-4ED9-B19C-A13763275556Q47330382-57D87A37-0ED3-49ED-9900-DDB216F5C2EBQ47833710-AC77CE3D-EF67-436C-BD33-A7C16C44BFDBQ48133925-C9D8269F-4406-4C98-8C06-066F0AA8B9C6Q48702423-67D470A0-65F8-4679-B510-90D78E856D74Q53149944-3FA0D6F5-B655-499C-8B1F-8E38822C69F8
P2860
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.
@ast
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.
@en
type
label
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.
@ast
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.
@en
prefLabel
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.
@ast
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.
@en
P2860
P356
P1476
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.
@en
P2093
P2860
P304
P356
10.1177/1758834011417039
P577
2011-11-01T00:00:00Z